Comparative Pharmacology
Head-to-head clinical analysis: DICHLORPHENAMIDE versus METHAZOLAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICHLORPHENAMIDE versus METHAZOLAMIDE.
DICHLORPHENAMIDE vs METHAZOLAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dichlorphenamide is a carbonic anhydrase inhibitor. It inhibits the enzyme carbonic anhydrase in the proximal renal tubule, reducing reabsorption of bicarbonate, leading to metabolic acidosis, and decreasing intraocular pressure by reducing aqueous humor formation.
Carbonic anhydrase inhibitor; reduces aqueous humor secretion by inhibiting carbonic anhydrase in ciliary processes, decreasing intraocular pressure.
25-50 mg orally twice daily.
Oral: 50-100 mg two to three times daily.
None Documented
None Documented
Terminal elimination half-life of 2-4 hours; increased in renal impairment, up to 12-24 hours in severe insufficiency.
Clinical Note
moderateMethazolamide + Etacrynic acid
"The risk or severity of adverse effects can be increased when Methazolamide is combined with Etacrynic acid."
Clinical Note
moderateMethazolamide + Bumetanide
"The risk or severity of adverse effects can be increased when Methazolamide is combined with Bumetanide."
Clinical Note
moderateMethazolamide + Hydrochlorothiazide
"The risk or severity of adverse effects can be increased when Methazolamide is combined with Hydrochlorothiazide."
Clinical Note
moderateTerminal half-life: 14-20 hours; approximately 15 hours in adults, prolonged in renal impairment
Primarily renal via tubular secretion; 50-70% excreted unchanged in urine; minor biliary/fecal elimination (<20%).
Renal: 70-90% as unchanged drug; minor biliary/fecal (<10%)
Category C
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor
Methazolamide + Indapamide
"The risk or severity of adverse effects can be increased when Methazolamide is combined with Indapamide."